Nashville, TNNCT07493447Now EnrollingIRB Ready

Meningioma Clinical Trial in Nashville, TN

Access cutting-edge meningioma treatment through this clinical trial at a research site in Nashville. Study-provided care at no cost to qualified participants.

Sponsored by Eben Rosenthal

Quick Self-Assessment

See if you qualify for this Nashville location

Preparing your pre-screening questions…

Expert Care in Nashville

Access meningioma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related meningioma treatment provided free

Apply for This Nashville Location

Check if you qualify for this meningioma clinical trial in Nashville, TN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Nashville

    Convenient for TN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Nashville site if eligible
  4. 4Begin participation

About This Meningioma Study in Nashville

This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.

Sponsor: Eben Rosenthal

Who Can Participate

Inclusion Criteria

Subjects with intracranial lesions undergoing surgical removal as their standard of care will be eligible. These may include subjects status post chemotherapy and/or radiation or subjects who have undergone diagnostic biopsy for their original diagnosis and are deemed to be candidates for resection.
Subject age ≥ 18 years.
Adequate hematologic and end-organ function appropriate for surgery and panitumumab infusion as determined by routine preoperative evaluation or designee prior to infusion. If liver function, renal function, and hematologic laboratory test results are acceptable for elective surgery and panitumumab infusion, the patient is considered eligible for the study. Laboratory results will need to be obtained within 30 days prior to initiation of study treatment include:
Chemistry Panel - Potassium, BUN (or urea), and Creatinine
CBC with differential - WBC, including ANC, hemoglobin, hematocrit, and platelet count
Magnesium and Phosphorus
Women of childbearing potential must have a negative pregnancy test within 7 days of study drug administration.
Ability to understand and willingness to sign a written informed document or written informed consent via a surrogate consent rider from the patients' healthcare decision maker.

Exclusion Criteria

Had a myocardial infarction, cerebrovascular accident, or uncontrolled chronic heart failure within 6 months prior to enrollment.
History of infusion reactions to any monoclonal antibody therapies.
Women who are currently pregnant or breastfeeding.
Participants presenting with a baseline QTcF interval \> than 480 milliseconds.
Magnesium or phosphorus lower than normal institutional values, and subject is symptomatic.
Patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.
Patients with severe renal disease or anuria

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Nashville?

Yes, this clinical trial (NCT07493447) has an active research site in Nashville, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Meningioma Treatment Options in Nashville, TN

If you're searching for meningioma treatment options in Nashville, TN, this clinical trial (NCT07493447) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Nashville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced meningioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all meningioma clinical trials near you to find additional studies recruiting in your area.

More Myalgic Encephalomyelitis Trials in Nashville, TN

See all myalgic encephalomyelitis clinical trials recruiting in Nashville — not just this study.

Browse Myalgic Encephalomyelitis Trials in Nashville →

Browse More Trials by Condition

Myalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Nashville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Nashville, TN